DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LOPRESSOR HCT

« Back to Dashboard

All Clinical Trials for Lopressor Hct

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00123604	Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes	Completed	GlaxoSmithKline	Phase 4	2004-06-01	The purpose of this study is to compare the vascular effects of two commonly used blood pressure medications, carvedilol and metoprolol in hypertensive patients with type 2 diabetes.
NCT00123604	Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes	Completed	St. Paul Heart Clinic	Phase 4	2004-06-01	The purpose of this study is to compare the vascular effects of two commonly used blood pressure medications, carvedilol and metoprolol in hypertensive patients with type 2 diabetes.
NCT00223717	Treatment of Supine Hypertension in Autonomic Failure	Recruiting	Vanderbilt University Medical Center	Phase 1/Phase 2	2001-06-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00589303	AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study	Terminated	Medtronic	Phase 3	2007-12-01	The purpose of this study is to determine whether early atrioventricular node (AVN) ablation with pacing device therapy will reduce death and hospitalization when compared to the conventional drug therapy in elderly patients with recurrent and symptomatic atrial fibrillation (AF).
NCT00589303	AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study	Terminated	Mayo Clinic	Phase 3	2007-12-01	The purpose of this study is to determine whether early atrioventricular node (AVN) ablation with pacing device therapy will reduce death and hospitalization when compared to the conventional drug therapy in elderly patients with recurrent and symptomatic atrial fibrillation (AF).
NCT00648271	Fed Study of Metoprolol Tartrate Tablets 25 mg and Lopressor® 50 mg	Completed	Mylan Pharmaceuticals	Phase 1	2002-12-01	The objective of this study was to investigate the bioequivalence of Mylan's metoprolol tartrate tablets to Novartis' Lopressor® tablets following a single, oral 50 mg (2 x 25 mg tablets for Mylan's formulation and 1 x 50 mg for Lopressor®) dose administered under fed conditions.

Clinical Trial Conditions for Lopressor Hct

Condition Name

Condition Name for Lopressor Hct
Intervention	Trials
Hypertension	8
Healthy	6
Atrial Fibrillation	4
Atrial Flutter	2

Condition MeSH

Condition MeSH for Lopressor Hct
Intervention	Trials
Hypertension	6
Atrial Fibrillation	4
Atrial Flutter	2
Pure Autonomic Failure	2

Clinical Trial Locations for Lopressor Hct

Trials by Country

Trials by Country for Lopressor Hct
Location	Trials
United States	24
Canada	4
France	1

Trials by US State

Trials by US State for Lopressor Hct
Location	Trials
West Virginia	3
Tennessee	3
Minnesota	3
North Dakota	2
Arizona	2

Clinical Trial Progress for Lopressor Hct

Clinical Trial Phase

Clinical Trial Phase for Lopressor Hct
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	2
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Lopressor Hct
Clinical Trial Phase	Trials
Completed	13
Recruiting	5
Active, not recruiting	1

Clinical Trial Sponsors for Lopressor Hct

Sponsor Name

Sponsor Name for Lopressor Hct
Sponsor	Trials
Forest Laboratories	4
Mylan Pharmaceuticals	4
University of Calgary	2

Sponsor Type

Sponsor Type for Lopressor Hct
Sponsor	Trials
Other	18
Industry	12